{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CytomX Therapeutics, Inc.
CytomX Therapeutics Hits New 52-Week High of $4.18, Up 150.92%
CytomX Therapeutics, Inc. achieved a new 52-week high of USD 4.18 on November 4, 2025, reflecting a significant annual stock performance increase. The company, with a market cap of USD 360 million, demonstrates strong financial metrics, including a favorable P/E ratio and a high return on equity.
CytomX Therapeutics Hits New 52-Week High at $4.16
CytomX Therapeutics, Inc. achieved a new 52-week high of USD 4.16 on November 3, 2025, reflecting a 141.1% increase over the past year. With a market cap of USD 360 million, the company demonstrates strong financial metrics, including a 40.02% return on equity and a debt-to-equity ratio of -1.27.
CytomX Therapeutics Hits New 52-Week High at $3.51, Up 109.82%
CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.51 on October 14, 2025, marking a significant increase from its previous low. With a market cap of USD 360 million, the company demonstrates strong profitability and a solid balance sheet, reflecting its growth in the Pharmaceuticals & Biotechnology sector.
CytomX Therapeutics Hits New 52-Week High of $3.48, Up 105.52%
CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.48 on October 1, 2025, reflecting a 105.52% increase over the past year. With a market capitalization of USD 360 million, the company shows strong financial metrics, including a P/E ratio of 10.00 and a return on equity of 40.02%.
CytomX Therapeutics Hits New 52-Week High at $3.28
CytomX Therapeutics, Inc. has achieved a new 52-week high of USD 3.28, reflecting a 95.71% increase over the past year. With a market capitalization of USD 360 million and a P/E ratio of 10.00, the company showcases strong financial health and effective capital management.
CytomX Therapeutics Hits New 52-Week High of $3.25, Up 77.91%
CytomX Therapeutics, Inc. achieved a new 52-week high of USD 3.25, reflecting strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen a 77.91% growth over the past year, significantly outperforming the S&P 500, and maintains solid financial metrics, including a P/E ratio of 10.00.
Is CytomX Therapeutics, Inc. technically bullish or bearish?
As of July 24, 2025, CytomX Therapeutics, Inc. shows a mildly bullish trend, supported by daily moving averages, despite mixed signals from weekly MACD and Bollinger Bands, while year-to-date performance is strong at 98.06%, though it has underperformed over the past 5 and 10 years.
Is CytomX Therapeutics, Inc. overvalued or undervalued?
As of September 3, 2025, CytomX Therapeutics, Inc. is considered very attractive in valuation due to its low P/E ratio of 10, favorable PEG ratio of 0.14, and strong EV to EBITDA ratio of 9.07, indicating significant growth potential despite a challenging long-term performance.
Is CytomX Therapeutics, Inc. overvalued or undervalued?
As of May 12, 2025, CytomX Therapeutics, Inc. is considered undervalued with a valuation grade upgrade to attractive, supported by strong financial ratios and a high ROE of 166.09%, despite a year-to-date return of 109.71% that significantly outperformed the S&P 500.
Is CytomX Therapeutics, Inc. technically bullish or bearish?
As of June 10, 2025, the technical trend is bullish with strong daily moving averages and a bullish weekly MACD, though caution is warranted due to bearish signals from the monthly RSI and mixed indicators in longer time frames.
Who are in the management team of CytomX Therapeutics, Inc.?
As of March 2022, the management team of CytomX Therapeutics, Inc. is led by Dr. Sean McCarthy as Chairman, President, and CEO, with Mr. Matthew Young as Lead Independent Director and additional independent directors including Dr. Mani Mohindru, Dr. Charles Fuchs, Ms. Halley Gilbert, and Mr. Frederick Gluck.
What does CytomX Therapeutics, Inc. do?
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, with a market cap of approximately USD 375 million. As of March 2025, it reported net sales of USD 51 million and a net profit of USD 24 million.
How big is CytomX Therapeutics, Inc.?
As of Jun 18, CytomX Therapeutics, Inc. has a market capitalization of 374.96 million, with net sales of 147.55 million and a net profit of 41.61 million over the last four quarters. The balance sheet indicates shareholder's funds of -0.46 million and total assets of 122.64 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
